⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 13, 2025

Table_S3 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis

Guadalupe Nibeyro Verónica M. Baronetto Agustín Nava María Romina Girotti Laura Prato Gabriel Morón Elmer A. Fernández

View Full Paper

Ask AI

Bookmark

Share

Key Points

Gene fusions serve as important prognostic biomarkers in patients with advanced melanoma, enhancing treatment strategies.
Analysis revealed distinct cohorts with varying outcomes based on low or high TFB status, indicating potential for tailored therapies.
Retrospective analysis across different patient cohorts examined the impact of gene fusions on treatment outcomes with immune checkpoint blockade.
Findings highlight the importance of gene fusions in advancing targeted therapies for melanoma, signaling a need for further research.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Retrospective analysis identifies gene fusions as prognostic biomarkers in advanced melanoma, suggesting roles in therapy.

Abstract

Number of patients from each cohort with Low/High TFB.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nibeyro et al. (2025) studied this question.

synapsesocial.com/papers/68a36a4f0a429f797332ef80 https://doi.org/10.1158/2767-9764.29900423

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table_S5 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis2025
2Table 1 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis2025
3Figure 2 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis2025
4Table_S4 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis2025
5Table S1 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis2025